Progress in precision #oncology depends on shared resources. @eaonc.bsky.social researchers are partnering with Caris Life Sciences to profile paired primary and recurrent breast tumors from two landmark trials, TAILORx and RxPONDER. During #BreastCancerAwareness learn more: bit.ly/ea1241-blog

The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM

EA1241, led by Dr. Joseph Sparano, is a companion study for patients who previously took part in either the TAILORx (PACCT-1) or RxPONDER (S1007) breast cancer trials. Learn more: https://bit.ly/EA1241

#FindingsFriday: Don’t miss the newest round-up of recently published findings from @eaonc.bsky.social #ClinicalTrials. See key #CancerResearch results and why they matter: bit.ly/3VUTsIs

Trial Results: ECOG-ACRIN Research Round-Up

Learn about the latest findings in leukemia, lung cancer and precision oncology

bit.ly

Can patients with high anatomic risk but low genomic risk for early-stage ER+/HER2- #breastcancer do similarly well without #chemotherapy? A new @eaonc.bsky.social #trial aims to evaluate the benefits for this subgroup.

Evaluating chemotherapy benefit in high-risk early-stage breast cancer

In the era of CDK4/6 inhibitors, the RxFINE-Low (EA1242) trial will evaluate whether chemotherapy provides additional benefit for patients with low genomic risk but high anatomic risk

healthcare-in-europe.com

Only about 7% of US patients with #cancer take part in #ClinicalTrials, and distance is a major barrier. Cooperative groups supported by The NCI's Community Oncology Research Program help bring trials to community sites closer to home. Learn more: bit.ly/3TqHCVU

Bringing Oncology Trials Closer to Home: Are We Rising to the Challenge?

A significant barrier to increasing oncology trial participation is a physical mismatch between sites with appropriate trial options and the locations where patients live and seek care. In order to re...

bit.ly

Monika Joshi, MD and Petros Grivas, MD, PhD are leading clinical trial EA8231, a phase 3 randomized trial comparing the effectiveness of pembrolizumab and sacituzumab govitecan to standard-of-care chemotherapy in patients with advanced urothelial cancer. https://bit.ly/ea8231-study

Consistent, evidence-based funding has helped deliver major advances in #cancer treatment. @acscan.bsky.social shares its perspective on a reported change to #NIH grantmaking and what it could mean for research: bit.ly/4xPN16S

ACS CAN Warns Political Interference Could Threaten Cancer Research

The American Cancer Society Cancer Action Network (ACS CAN) today expressed deep concern following media reports of a new planned executive order placing greater political control over research grant ...

bit.ly

Thank you for sharing our powerful five-minute video @eaonc.bsky.social! I really helps frame clinical trials from the participant's point of view.

ECOG-ACRIN Cancer Research Group@eaonc.bsky.social · 4w ago

Powerful video by our colleagues at @alliance-org.bsky.social! #Cancer #ClinicalTrial participation can save lives.

The #BreastCancer study EA1242/RxFINE-Low is testing whether hormone therapy plus ribociclib, without chemotherapy, is as effective as standard treatment that includes chemotherapy. Learn more: https://bit.ly/ea1242-study

#ClinicalTrial EA5221/ACHIEVE, led by Dr. Megan Baumgart, aims to help older patients with #LungCancer live longer while also maintaining a good quality of life. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM

#ClinicalTrial EA7211/STRASS 2, led in the US by Dr. Kenneth Cardona, is the second randomized study ever performed in retroperitoneal soft tissue #sarcoma & is enrolling patients in the US, Europe, Canada, Australia, New Zealand, & Japan! Learn more: https://bit.ly/EA7211

#FindingsFriday: New research from 9 ECOG-ACRIN Cancer Research Group trials found most patients who smoked before their #cancer diagnosis kept smoking—during and after treatment. #SmokingCessation support needs to be built into cancer care, not left to chance. Learn more: https://bit.ly/4dvJZxj

ICYMI, more than a decade after TAILORx changed #BreastCancer care, its biorepository is yielding new insights: researchers used #AI to review archived pathology slides from 4,000+ trial participants, developing a more accurate recurrence-risk model. More: https://bit.ly/4cY42EB

A new AI-powered test offers more accurate prediction of breast cancer recurrence risk

Learn how ECOG-ACRIN is using an innovative artificial intelligence (AI) model to create more accurate recurrence risk predictions in patients with early-stage breast cancer.

bit.ly

EA8231 is a phase 3 study comparing pembrolizumab & sacituzumab govitecan versus standard chemotherapy in patients with advanced urothelial cancer. The trial aims to improve treatment options & guide further research. ➡️ https://bit.ly/ea8231-study

Decades of federal investment in #CancerResearch have saved millions of lives. American Association for Cancer Research (AACR)'s Cancer Progress Report asks Congress to sustain NIH/NCI funding & protect grants from interference—because progress against #cancer depends on it. https://bit.ly/4xC3bRk

Do you have #BreastCancer that was recently removed by surgery? If so, you may be eligible for clinical trial EA1242/RxFINE-Low, a study exploring potential new treatment approaches. More info: https://bit.ly/ea1242-study

Do you have advanced non-small cell #LungCancer and are age 70 or older? If so, you may be able to participate in this study of a new treatment approach. Learn more: https://bit.ly/ea5221-achieve

Can patients with high-risk retroperitoneal #sarcoma benefit from neoadjuvant chemotherapy? The international EA7211/STRASS 2 #ClinicalTrial, led in the US by Dr. Kenneth Cardona aims to find out. More: https://bit.ly/EA7211 cc: European Organisation for Research and Treatment of Cancer

#FindingsFriday: New results from CompassHER2 pCR help identify factors associated w/ pathologic complete response in HER2+ #BreastCancer. Research like this moves us closer to more personalized treatment strategies. More in JCO Journals: https://bit.ly/4hqJjM3 #ClinicalTrials

#CancerResearch advances through collaboration. In our latest Institution Spotlight, Dr. Joseph Sparano shares how the Mount Sinai Tisch Cancer Center is contributing to NCI-funded clinical research, incl. the ongoing EA1241 trial, while helping cultivate future leaders. More: https://bit.ly/4xt4ty2

Institution Spotlight: Mount Sinai Tisch Cancer Center

Showcasing the center's commitment to training oncology researchers and improving patient outcomes through impactful cancer clinical trials

bit.ly

Clinical trial EA8231, led by Monika Joshi, MD and Petros Grivas, MD, PhD, is a phase 3 randomized study exploring a new treatment approach for pts with treatment-refractory, locally-advanced or metastatic urothelial cancer. More information here: https://bit.ly/ea8231-study

Powerful video by our colleagues at @alliance-org.bsky.social! #Cancer #ClinicalTrial participation can save lives.

Alliance for Clinical Trials in Oncology@alliance-org.bsky.social · last mo.

Clinical trials help advance cancer research and care—but they depend on people willing to participate. Our new film shares one participant’s story and the vital role volunteers play in improving cancer treatment. You can view the five-minute #RewritingCancer film here: https://bit.ly/Alliance-Video

Clinical trial EA1242/RxFINE-Low, led by Dr. Nancy Chan of Perlmutter Cancer Center at NYU Langone Health, is testing whether hormone therapy plus ribociclib is as effective as chemotherapy followed by hormone therapy plus ribociclib in patients with #BreastCancer. More: https://bit.ly/ea1242-study

The EA5221/ACHIEVE clinical study is testing two different treatment approaches for older adults with advanced non-small cell #LungCancer. Learn more: https://bit.ly/ea5221-achieve #NSCLC #LCSM

#CancerResearch progress is not guaranteed. As the American Society of Clinical Oncology's Save Research campaign highlights, continued federal investment is critical to supporting researchers, fueling innovation, & advancing #ClinicalTrials. More: https://bit.ly/3V9APjK #SaveResearchStopCancer

‘Save Research’ Campaign Champions Federal Funding

ASCO members are leading the way to make sure Congress understands the critical importance of federal cancer research funding before the September 30 federal funding deadline.    

bit.ly

In #ClinicalTrial EA7211/STRASS 2, investigators are testing neoadjuvant chemotherapy followed by surgery vs. surgery alone for patients with high-risk retroperitoneal #sarcoma. More info: https://bit.ly/EA7211

Encouraging news: #cancer survival rates among adolescents & young adults (#AYAs) continue to improve. Study authors: "Much of this progress can be attributed to national efforts led by NCI-funded cooperative groups to focus on AYA oncology." bit.ly/3TfrypP #AYACancer

Young Adult Cancer Survival Rates Accelerate

Researchers have analyzed annual survival data between AYA patients aged 15-39 years and patients in younger and older age groups between 1975 and 2017.

bit.ly

#Cancer #ClinicalTrials depend on a strong & stable research infrastructure. Consistent federal funding helps support the #science that brings innovative treatments to patients & advances cancer care. @americancancersoc.bsky.social is urging Congress to pass a full-year budget: bit.ly/4yr6sn9

ACS CAN Calls on Congress to Pass Full-Year Budget; Preserve Stability in Federal Research Funding

Today, the House passed a continuing resolution (CR) to fund the federal government through mid-December.

bit.ly

Federal investment in #cancer #ClinicalTrials matters. A recent study found that federally funded trials are more likely to examine rare & pediatric cancers, prevention strategies, supportive care, & ways to reduce treatment burden. More via @theaacr.bsky.social's blog: bit.ly/4zS7fzm

Unboxing Cancer News, August 2026: Fishy Cancer, Federal- vs. Industry-funded Trials, and More

The August 2026 edition of “Unboxing Cancer News” highlights a transmissible cancer, federal- vs. industry-funded clinical trials, and more.

bit.ly